Bayer's Funding Engine Revs Up as a Missouri Judge Holds the Key to $7.25 Billion

Bayer placed EUR 2 billion in hybrid bonds and advanced asset sales, but its outlook hinges on a Missouri judge's pending ruling on the $7.25 billion Roundup settlement.

Bayer has spent the past several weeks doing what a leveraged conglomerate does when it wants to keep its options open: raising money, selling assets, and buying pipeline. On Wednesday the Leverkusen-based group placed two hybrid bonds worth a combined EUR 2 billion, and demand was heavy enough that both tranches closed multiple times oversubscribed, according to company statements. Proceeds are earmarked for general corporate purposes.

The issue splits into two EUR 1 billion tranches, each running 30 years, with coupons set at 5.75% and 6.25%. The transaction lifts Bayer's outstanding hybrid bond volume to EUR 6.55 billion, a meaningful addition to a capital structure that has drawn scrutiny ever since the glyphosate litigation began weighing on the balance sheet.

That financing push lands alongside a broader portfolio overhaul. Apollo Funds and KKR wrapped up a EUR 3 billion capital solution in mid-September for Bayer's long-acting reversible contraceptive business, a partnership in which Bayer retains operational control and a majority stake in the newly formed entity. Media reports also point to a minority stake sale in the same LARC unit to Apollo, expected to close in the third quarter of 2026, which would bring in EUR 3.0 billion of equity. Separately, Bayer recently completed the divestment of the cancer drug Stivarga to Grünenthal for up to EUR 375 million, with closing targeted for late 2026 or early 2027.

A courtroom in Missouri, a balance sheet in Leverkusen

The thread tying these moves together runs through a federal courtroom in Missouri, where a hearing was held in mid-September on final approval of the proposed $7.25 billion Roundup settlement. No ruling has been issued yet, and the timing of a decision remains unclear. For Bayer, this is the single most consequential catalyst of the year — the difference between drawing a line under years of glyphosate litigation and facing another stretch of open-ended legal exposure.

The financial logic is straightforward. Only once the settlement is finalized can Bayer reliably quantify the cash needed to resolve the claims. Until the judge rules, the valuation discount on the agricultural division stays in place, and that discount colors how the market prices the entire DAX group. Uncertainty over timing and the possibility of amended terms continues to cap investor confidence.

Not everyone is waiting on the sidelines. Amundi crossed the 3% voting rights threshold in mid-September and now holds 3.04% of Bayer, a disclosure that suggests at least some large institutions are sizing up how much legal risk is already baked into the current share price.

Pipeline progress on two fronts

Operationally, Bayer has kept its core divisions moving. In pharmaceuticals, the FDA granted accelerated approval in early September for Sevabertinib, a cancer drug indicated for first-line treatment of adults with HER2-mutated non-small cell lung cancer. The company also agreed in May to acquire Perfuse Therapeutics for up to $2.45 billion, including a $300 million upfront payment — a deal that could strengthen the pharma pipeline for years to come.

In Crop Science, Bayer is preparing to roll out additional products including Vyconic and Intacta 5+, part of an effort to modernize its agricultural portfolio.

The bull case rests on the Missouri judge signing off on the $7.25 billion package without onerous conditions. That outcome would free management — under CFO Judith Hartmann, in the role since late May — to accelerate the strategic realignment and give the stock room to test its 52-week high of EUR 53.86. Shares closed yesterday at EUR 49.50, up 34% since the start of the year, and sit roughly 16% above their 200-day moving average of EUR 42.72.

What a rejection would cost

The bear case is a delay or partial rejection of the settlement. If the judge objects to significant portions of the package, renegotiation or a revival of individual jury trials becomes plausible. That would put the $7.25 billion figure in doubt and could require additional cash outlays.

Operating momentum is already uneven. In the second quarter of 2026, adjusted earnings in the pharma division fell 3.6%. Group revenue came in at EUR 10.87 billion, while adjusted EBITDA rose just 1.9% to EUR 2.14 billion. Should the glyphosate compromise collapse, the confirmed full-year 2026 targets — adjusted EBITDA of EUR 9.6 billion to EUR 10.1 billion and core earnings per share of EUR 4.30 to EUR 4.90 — would come under sharper scrutiny. In that scenario, the market could push divestment progress to the background and refocus on the company's heavy debt load.

For now, with the Missouri ruling outstanding and approval widely viewed as likely, the broader recovery trend holds. The next decisive catalysts are the court's order in Missouri and the planned closing of the Apollo deal at the end of the third quarter of 2026. Until the US judiciary provides clarity, Bayer's long-term upside remains contingent on a gavel.